Riskpilot← Back to searchSign inGet full accessCIRCIUS PHARMA AS
ASActiveOrg 927538075Askimveien 932, 1811 AskimWholesale of pharmaceutical and medical goods · NACE 4646Est. 20211 employees
Revenue 2024
NOK 13M
-20% vs 2023
EBITDA margin
1.5%
-15% vs 2023
Equity ratio
26.8%
Financial strength
Net profit 2024
NOK 0
1 employees
| Revenue | NOK 13M | -20% |
| EBITDA | NOK 189K | -15% |
| Net profit | NOK 0 | — |
| Total assets | NOK 7,6M | +16% |
| Equity | NOK 2M | +0% |
| Employees | 1 | — |
Legal name
CIRCIUS PHARMA AS
Org number
927538075
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. september 2021
Share capital
NOK 300 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Markedsføring og salg av plantebaserte legemidler, legemiddel, medisintekniske produkter og kosttilskudd samt det som naturlig står i forbindelse med dette.
Address
Askimveien 932, 1811 Askim
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 2 903 | 15 980 | 16 174 | 12 976 |
| Staff expenses | −490 | −1 383 | −1 506 | −1 547 |
| EBITDA | −231 | 226 | 223 | 189 |
| Depreciation & amort. | −73 | −218 | −218 | −218 |
| EBIT | −304 | 7 | 5 | −30 |
| Net financials | −0 | −8 | −5 | 30 |
| Profit before tax | −304 | −0 | 0 | 0 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −304 | −0 | 0 | 0 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 5 105 | 5 388 | 6 602 | 7 648 |
| Equity | −54 | 2 046 | 2 046 | 2 046 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 5 159 | 3 342 | 4 555 | 5 602 |
| Total debt | 5 159 | 3 342 | 4 555 | 5 602 |
EBITDA margin
1.5%
This company
15.8%
Market median
-91% vs market
20212024
Equity ratio
26.8%
This company
38.2%
Market median
-30% vs market
20212024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20212024
Asset turnover
1.70×
This company
1.12×
Market median
+52% vs market
20212024
Debt / equity
2.74×
This company
0.62×
Market median
-342% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EH Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2023 | |
| Former (1) | ||
| Board of Directors | 2021 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Circius Pharma Ab | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CIRCIUS PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Espen Haugerud | Chief Executive Officer | 0 companies |
| Jan Gustav Smith | Chairman | 0 companies |
| Jörgen Mikael Carlson | Board of Directors | 0 companies |
| Jan Erik Gustav Smith | Board of Directors | 0 companies |
| Johan Henning Lindberg | Board of Directors | 0 companies |